CGT的冰与火之歌:终点有蓬勃璀璨,过程直面“惨烈洗牌”。撤退潮中,行业领军人物“杀回”,新的竞速拉开序幕。图源:pexels年入65亿的CRO实际裁员600人,含“CGT团队”Guide View去年,年入近8亿欧元(65亿元)的德国药物发现及合同开发制造(CRO/CDMO)公司Evotec为应对全球新药早期研究支出放缓的挑战,提出实施大规模重组,目标是在2025年前节省至少4000万欧元的成本...
Source LinkCGT的冰与火之歌:终点有蓬勃璀璨,过程直面“惨烈洗牌”。撤退潮中,行业领军人物“杀回”,新的竞速拉开序幕。图源:pexels年入65亿的CRO实际裁员600人,含“CGT团队”Guide View去年,年入近8亿欧元(65亿元)的德国药物发现及合同开发制造(CRO/CDMO)公司Evotec为应对全球新药早期研究支出放缓的挑战,提出实施大规模重组,目标是在2025年前节省至少4000万欧元的成本...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.